Arthritis encompasses inflammatory joint diseases (rheumatoid, psoriatic) and degenerative cartilage breakdown (osteoarthritis), driven by synovial inflammation, cytokine excess, cartilage matrix degradation, and impaired tissue repair. Peptide research targets both the inflammatory cascade and the regenerative deficit — reducing joint inflammation while stimulating the collagen and matrix remodeling needed for durable recovery.
1. BPC-157 — Anti-Inflammatory / Synovial Healing
BPC-157 downregulates NF-κB-driven pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in synovial tissue and promotes angiogenesis critical for cartilage repair. Multiple animal models show dramatic reduction in arthritis-associated joint inflammation and restoration of range of motion after BPC-157 administration.
Dosing Protocol: 250–500 mcg SubQ once daily, injected as close to the affected joint as practical. For systemic inflammation, 500 mcg oral (arginate form) targets the GI-systemic inflammatory axis. Cycle: 4–8 weeks.
2. TB-500 — Connective Tissue Repair / Anti-Inflammatory
TB-500 (Thymosin Beta-4) regulates actin polymerization, reduces inflammatory cytokines in connective tissue, and promotes tendon, ligament, and cartilage repair. It accelerates the migration of repair cells to damaged joint structures and reduces the fibrosis that stiffens arthritic joints over time.
Dosing Protocol: 2–2.5 mg SubQ twice weekly for 4–6 weeks (loading phase), then 2 mg once weekly for maintenance. Best combined with BPC-157 for synergistic joint healing.
3. GHK-Cu — Cartilage Matrix / Collagen Synthesis
GHK-Cu stimulates collagen type I, II, and III synthesis — the structural proteins of cartilage and joint matrix. It also activates matrix metalloproteinase inhibitors that prevent further cartilage breakdown and has demonstrated anti-inflammatory effects in chondrocytes, the cells responsible for maintaining cartilage health.
Dosing Protocol: 1–2 mg SubQ daily, or topical application over affected joints (1–2% cream). SubQ preferred for deeper joint penetration. Cycle: 8–12 weeks.
4. KPV — Targeted Joint Anti-Inflammatory
KPV (Lys-Pro-Val) is a potent anti-inflammatory tripeptide that directly inhibits NF-κB activation in synovial tissue and immune cells within the joint. It suppresses the release of IL-6, IL-8, and TNF-α — the primary cytokines driving joint destruction in both osteoarthritis and rheumatoid arthritis — without the systemic side effects of NSAIDs or corticosteroids.
Dosing Protocol: 200–500 mcg SubQ daily, ideally near the affected joint. For systemic arthritic inflammation, oral KPV (500 mcg) can be used to target gut-driven immune activation. Cycle: 6–8 weeks.
BPC-157 and TB-500 form the repair foundation — BPC-157 suppresses the cytokine-driven synovial inflammation while TB-500 accelerates connective tissue remodeling and prevents fibrotic stiffness. GHK-Cu rebuilds the degraded collagen matrix at the heart of cartilage breakdown. KPV delivers targeted NF-κB suppression directly within the joint environment — amplifying the anti-inflammatory effects of BPC-157 with a complementary mechanism that specifically neutralizes the cytokines driving articular destruction.
- Chang CH et al. (2018). BPC-157 and joint healing in rat models. Journal of Orthopaedic Translation. DOI: 10.1016/j.jot.2018.01.001
- Goldstein AL et al. (2010). Thymosin beta-4 and connective tissue repair. Peptides. DOI: 10.1016/j.peptides.2010.05.006
- Pickart L et al. (2018). GHK-Cu and collagen synthesis in joint tissue. Int J Mol Sci. DOI: 10.3390/ijms19071987
- Getting SJ et al. (2004). KPV inhibits NF-κB in inflammatory joint cells. Journal of Biological Chemistry. DOI: 10.1074/jbc.M400521200
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).